181 related articles for article (PubMed ID: 9933658)
1. A PET study of 18FDG uptake in soft tissue masses.
Lodge MA; Lucas JD; Marsden PK; Cronin BF; O'Doherty MJ; Smith MA
Eur J Nucl Med; 1999 Jan; 26(1):22-30. PubMed ID: 9933658
[TBL] [Abstract][Full Text] [Related]
2. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
[TBL] [Abstract][Full Text] [Related]
3. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible?
Schulte M; Brecht-Krauss D; Heymer B; Guhlmann A; Hartwig E; Sarkar MR; Diederichs CG; Schultheiss M; Kotzerke J; Reske SN
Eur J Nucl Med; 1999 Jun; 26(6):599-605. PubMed ID: 10369945
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of several FDG PET parameters for prediction of soft tissue tumour grade at primary diagnosis and recurrence.
Fendler WP; Chalkidis RP; Ilhan H; Knösel T; Herrmann K; Issels RD; Bartenstein P; Cyran CC; Lindner LH; Hacker M
Eur Radiol; 2015 Aug; 25(8):2214-21. PubMed ID: 25693667
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
[TBL] [Abstract][Full Text] [Related]
8. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography.
Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Hasegawa T
Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):683-91. PubMed ID: 16506050
[TBL] [Abstract][Full Text] [Related]
9. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis.
Wu H; Dimitrakopoulou-Strauss A; Heichel TO; Lehner B; Bernd L; Ewerbeck V; Burger C; Strauss LG
Eur J Nucl Med; 2001 Jun; 28(6):704-10. PubMed ID: 11440030
[TBL] [Abstract][Full Text] [Related]
10. 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET.
Zhang H; Tian M; Oriuchi N; Higuchi T; Watanabe H; Aoki J; Tanada S; Endo K
Nucl Med Commun; 2003 Mar; 24(3):273-9. PubMed ID: 12612468
[TBL] [Abstract][Full Text] [Related]
11. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading.
Dimitrakopoulou-Strauss A; Strauss LG; Schwarzbach M; Burger C; Heichel T; Willeke F; Mechtersheimer G; Lehnert T
J Nucl Med; 2001 May; 42(5):713-20. PubMed ID: 11337565
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography.
Lucas JD; O'Doherty MJ; Cronin BF; Marsden PK; Lodge MA; McKee PH; Smith MA
Br J Surg; 1999 Apr; 86(4):550-6. PubMed ID: 10215835
[TBL] [Abstract][Full Text] [Related]
13. Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning.
Watanabe H; Shinozaki T; Yanagawa T; Aoki J; Tokunaga M; Inoue T; Endo K; Mohara S; Sano K; Takagishi K
J Bone Joint Surg Br; 2000 Jul; 82(5):760-7. PubMed ID: 10963181
[TBL] [Abstract][Full Text] [Related]
14. Can FDG PET be used to successfully direct preoperative biopsy of soft tissue tumours?
Hain SF; O'Doherty MJ; Bingham J; Chinyama C; Smith MA
Nucl Med Commun; 2003 Nov; 24(11):1139-43. PubMed ID: 14569167
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses.
Aoki J; Watanabe H; Shinozaki T; Takagishi K; Tokunaga M; Koyama Y; Sato N; Endo K
Skeletal Radiol; 2003 Mar; 32(3):133-8. PubMed ID: 12605276
[TBL] [Abstract][Full Text] [Related]
16. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine.
Buck AK; Herrmann K; Büschenfelde CM; Juweid ME; Bischoff M; Glatting G; Weirich G; Möller P; Wester HJ; Scheidhauer K; Dechow T; Peschel C; Schwaiger M; Reske SN
Clin Cancer Res; 2008 May; 14(10):2970-7. PubMed ID: 18445694
[TBL] [Abstract][Full Text] [Related]
17. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.
Nakamoto Y; Higashi T; Sakahara H; Tamaki N; Kogire M; Doi R; Hosotani R; Imamura M; Konishi J
Cancer; 2000 Dec; 89(12):2547-54. PubMed ID: 11135214
[TBL] [Abstract][Full Text] [Related]
18. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma.
Dancheva Z; Bochev P; Chaushev B; Yordanova T; Klisarova A
Nucl Med Rev Cent East Eur; 2016; 19(1):22-7. PubMed ID: 26841376
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors.
Tian M; Zhang H; Oriuchi N; Higuchi T; Endo K
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1064-72. PubMed ID: 15014903
[TBL] [Abstract][Full Text] [Related]
20. Assessment of soft tissue lesions suspicious for liposarcoma by F18-deoxyglucose (FDG) positron emission tomography (PET).
Schwarzbach MH; Dimitrakopoulou-Strauss A; Mechtersheimer G; Hinz U; Willeke F; Cardona S; Attigah N; Strauss LG; Herfarth C; Lehnert T
Anticancer Res; 2001; 21(5):3609-14. PubMed ID: 11848531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]